Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and Phosphate: Hormone Feedback, Bone and Energy: Full Evidence Review

Previous related pageVitamin D and Phosphate: Hormone Feedback, Bone and Energy: Study SummaryNext related pageVitamin D and Phosphate: Hormone Feedback, Bone and Energy: Study Summary
Study at a glance

What was studied?

Researchers studied vitamin D, hormones and phosphate, a substance used in bone mineral and energy-transfer molecules. The evidence included human trials, rat and mouse experiments, and bone samples from adults with a rare condition that causes excessive phosphate loss.

What did the studies find?

One vitamin D2 trial increased a phosphate-regulating hormone. A separate D3 trial used a different test and did not find a clear overall change in that hormone. These were different studies, not a direct D2-versus-D3 comparison. In mice, blood phosphate could stay steady while absorption and loss in urine changed.

What does this mean?

Organs and hormones influence phosphate handling together. A blood result does not measure every change in absorption, loss or tissue use. High blood phosphate could occur with poor addition of mineral to bone. Improvement in one measurement did not guarantee improvement in every tissue.

What are the limits?

Removing a gene in an animal, giving active hormone and giving a form that the body must convert are different tests. The small human bone study tested treatment directed at a phosphate-regulating hormone, not D3. The findings do not establish a personal dose or prove that D3 improves muscle energy.

Read the full article below ↓

Vitamin D participates in a phosphate-regulating system that connects intestinal absorption, kidney excretion, parathyroid hormone and the bone-derived hormone FGF23. The evidence describes conditional feedback, changes in mineral handling and consequences for bone and muscle metabolism. Different experiments test different parts of this system: a receptor or hormone deletion in a mouse, a precursor supplement in people and treatment of a rare phosphate-wasting disease are separate interventions. For the shorter account, read Vitamin D and Phosphate: Hormone Feedback, Bone and Energy: Study Summary.

How vitamin D, FGF23 and PTH coordinate phosphate

Phosphate regulation is a question about movement as well as concentration. The intestine supplies absorbed phosphate, and the kidneys adjust how much filtered phosphate returns to the blood. A blood result is therefore one measurement within an actively regulated system. It does not directly measure intestinal transport, urinary loss, tissue incorporation or the amount available inside a muscle cell. Vitamin D and Kidneys provides the kidney context for these distinctions.

The studies considered here examine native vitamin D precursors, activated vitamin D and the responses of particular organs. Ergocalciferol is vitamin D2, cholecalciferol is vitamin D3, and calcitriol is the activated hormone. Their identity matters. Giving a precursor leaves conversion and feedback processes in place; directly supplying calcitriol changes the exposure more immediately. Vitamin D Activation explains that conversion background. The experiments below do not establish a personal supplement regimen.

FGF23 and parathyroid hormone, abbreviated PTH, interact with this system. Their effects depend on the responding organ and its state. The most useful account combines experiments that establish particular regulatory relationships with human studies that test whether an intervention produces the expected net response. It also retains experiments in which a response is absent or differs between transport routes.

Removing FGF23 changes renal handling and activated vitamin D

Shimada and colleagues removed Fgf23 throughout mice and followed the resulting biochemical and skeletal changes. The animals developed high blood phosphate and calcitriol, increased renal phosphate reabsorption and changes in kidney phosphate transport machinery. Phosphate and calcitriol abnormalities appeared early, before the later fall in PTH. This temporal order limits an explanation in which the entire phenotype begins with reduced PTH.

The investigators measured renal transport as well as circulating substances. Phosphate uptake in kidney brush-border preparations was approximately 632.6 versus 396.4 pmol per mg protein per minute in knockout and control groups, respectively. The small assay groups contained six and five animals. These measurements support altered renal handling in that model; they are more specific than concluding that every consequence arose because a blood concentration was high.

This was a severe developmental whole-body deletion. Calcium, phosphate, calcitriol and PTH did not vary independently, and the animals were markedly unwell. A low-phosphate diet prolonged survival without removing all abnormalities. The experiment establishes an important regulatory role for FGF23, while leaving several interacting contributors to the final phenotype. It cannot estimate the effect of ordinary vitamin D3 supplementation in people.

Human precursor trials show both a response and an overall null result

Burnett-Bowie and colleagues studied 50,000 international units (IU) of vitamin D2 weekly for twelve weeks versus placebo in healthy adults aged eighteen to forty-five, recruited after a low 25-hydroxyvitamin D screening result. Screening and baseline assays differed, an important eligibility limitation. Ninety participants completed the trial, with forty receiving D2 and fifty placebo. Intact FGF23 increased relative to placebo, alongside changes in vitamin D metabolites. The reported between-group FGF23 result was statistically clear, with P=.003. This describes the study exposure, not an individual supplement instruction.

The functional interpretation was more limited. Fractional phosphate excretion rose within the D2 group, but the between-group comparison did not clearly establish an excretion effect. Blood phosphate, PTH and calcium likewise did not show clear between-group differences. A within-group change cannot be substituted for the randomized comparison. An endocrine response can occur without a demonstrated change in every downstream measurement.

Trummer and colleagues examined a different intervention and population: 2,800 IU vitamin D3 daily for eight weeks versus placebo in adults with hypertension. This post-hoc analysis had paired FGF23 results for 181 participants, ninety assigned D3 and ninety-one placebo. The overall adjusted C-terminal FGF23 effect was 0.374 pmol/L, with a 95% confidence interval from -0.024 to 0.772 and P=.065. The overall result therefore did not clearly establish an increase.

Exploratory lower-status subgroup results do not replace that overall finding. The report also contains an awkward subgroup confidence-interval and P-value presentation, which prevents a clean precise claim about that subgroup. The two trials used different vitamin D forms, schedules, populations and FGF23 assays. Their contrast cannot establish that D2 and D3 inherently have opposite effects on FGF23.

Dietary loading separates blood concentrations from excretion

Gerber and colleagues used a controlled crossover study in ten healthy young men. Each participant experienced the five-day dietary conditions, separated by a washout period. Higher phosphate exposure was compared with a lower-availability condition that included a phosphate binder. This was a repeated-person comparison, not twenty independent participants.

The higher-phosphate condition increased serum phosphate, fractional phosphate excretion and intact FGF23. Fractional excretion averaged 22.5% versus 13.6%, with P=.0001. None of these four measurements showed a clear difference between conditions: PTH, calcitriol, the renal threshold measure TmP/GFR and C-terminal FGF23. The studies used different laboratory tests. “Intact” means the whole FGF23 molecule, while “C-terminal” refers to one end of the molecule. These tests provide different molecular readouts; one result should not be silently substituted for the other.

The design was short and male-only, with a binder-containing comparator. A separate unintended sodium-balancing error also produced a difference between the menus. Low vitamin D status had been corrected beforehand. The study therefore cannot show how every deficient or kidney-impaired population would respond. Its contribution is to demonstrate coordinated, selective adaptation under controlled conditions, including disagreement between measurements often treated as interchangeable.

A normal parathyroid gland and a uremic gland respond differently

Ben-Dov and colleagues showed that FGF23 could suppress PTH in normal rats and isolated parathyroid glands. They combined secretion measurements with experiments addressing intracellular signalling. The findings support a direct normal-gland component of the feedback system. In the five-day comparison, serum phosphate was 3.03 mmol/L in controls and 2.64 mmol/L in FGF23-treated animals; the groups were small and calcium did not show a clear change.

Canalejo and colleagues then provide an important disease-context qualification. In rats with severe experimental renal failure, FGF23 did not clearly suppress PTH in uremic glands, although normal glands responded. Resistance accompanied altered receptor-related expression and failure of the examined signalling response. Those associations help explain the observed contrast, but do not establish one exclusive cause of resistance.

The normal and diseased models cannot be combined into an unconditional arrow stating that more FGF23 always lowers PTH. The uremic experiment also involved mineral abnormalities, gland enlargement and a severe renal model. It does not establish the same receptor-expression pattern in every person with chronic kidney disease. Vitamin D and Calcium Physiology helps place these interacting calcium, phosphate and hormone responses in their wider physiological setting.

Calcitriol changes active transport without increasing every absorption route

Hernando and colleagues compared normal mice with mice lacking the intestinal phosphate transporter NaPi-IIb. They measured intestinal transport and permeability, transporter expression, hormones and renal handling after short-term calcitriol exposure. This separates a transport mechanism from a conclusion based only on gene expression.

Calcitriol increased active phosphate uptake in the jejunum of normal mice, while that response was absent after intestinal transporter deletion. Passive phosphate absorption did not increase in the same way. Both genotypes showed endocrine and renal adaptations, including increased FGF23, reduced PTH and greater phosphate excretion, while serum phosphate remained stable.

Stable blood phosphate therefore did not mean that transport and excretion were unchanged. Equally, activation of one intestinal route did not demonstrate that every route was vitamin-D responsive. This was a short pharmacological active-hormone experiment in male mice; the contribution of particular circulating mediators was inferred rather than established by selectively blocking each one. Vitamin D Receptors supplies the receptor background, while these results retain their own tissue and intervention boundaries.

What altered phosphate handling does to bone and systemic metabolism

Regulation matters because tissues use phosphate under different conditions and on different timescales. The second scientific question is what happens when handling is disrupted. The selected evidence includes developing cartilage, abnormal bone mineralisation, a human phosphate-wasting disease, and muscle responses to deficient or excessive phosphate. These outcomes must remain attached to their particular interventions.

Vitamin D and Bone provides the broad skeletal setting. The detailed comparison in Vitamin D and Bone: Mineralisation, Cell Signalling and Fractures: Full Study also addresses bone-cell signalling and human fractures. The question here is more specific: how phosphate availability and its hormonal regulation relate to mineralisation and systemic metabolic consequences. A mineralisation result is not automatically a fracture result.

Growth-plate maturation depends on mineral availability

Sabbagh and colleagues compared several mouse models, including vitamin D receptor deficiency, a phosphate-wasting genetic model and dietary phosphate restriction. They also studied cartilage cells at different stages of development. In the phosphate-deficient settings, the normal removal of enlarged growth-plate cartilage cells was impaired, contributing to an expanded abnormal growth plate.

This work distinguished phosphate availability from a simple claim that every growth-plate defect must arise directly inside a vitamin-D-responsive cell. Mineral rescue corrected the growth-plate abnormality in receptor-deficient mice. The phosphate-wasting and dietary models also showed abnormalities without the same calcium or PTH pattern. The results support a phosphate-dependent contribution to the developmental process.

The cellular experiments implicated caspase-associated apoptosis, a regulated process of cell removal. Their effect depended on cell differentiation state. A response in these experimental growth-plate cells does not establish what happens in adult human bone or quantify fracture prevention. Multiple models within this publication provide complementary tests; they are not several independent clinical studies.

The earlier Fgf23-deletion experiment adds a different warning. Its animals had high circulating phosphate and calcitriol yet poor skeletal mineralisation and accumulated unmineralised matrix, called osteoid. High blood mineral availability alone did not guarantee appropriate tissue deposition. The severe whole-body disturbance prevents assigning that paradox to a single substance.

Correcting calcification can leave a worse skeletal problem

Sitara and colleagues crossed Fgf23-deficient mice with mice lacking the vitamin D activating enzyme Cyp27b1. Removing activation altered the excessive hormonal and mineral state and eliminated the observed ectopic calcification. Ectopic calcification means mineral deposition in locations outside the normal skeleton.

That improvement did not mean that the whole animal’s mineral physiology had been normalised. The double-knockout animals developed low calcium, high PTH and worse rickets or osteomalacia. The experiment therefore shows opposing tissue consequences within one regulatory intervention: less inappropriate calcification accompanied a more severe skeletal mineralisation problem.

Phosphate, calcium, calcitriol and PTH changed together. This is not an isolated test of lowering phosphate, nor a model from which to derive a nutritional vitamin D regimen. It demonstrates why choosing one favourable endpoint can conceal an important cost elsewhere. The relevant clinical question would need its own intervention, population and outcomes.

Human XLH biopsy evidence improves the clinical connection

Insogna and colleagues studied adults with X-linked hypophosphataemia, abbreviated XLH, a disease involving excessive renal phosphate loss. Their single-arm trial examined burosumab, an FGF23-directed treatment. It did not test native vitamin D3 supplementation, and the treatment changed phosphate and calcitriol together.

Fourteen adults enrolled and thirteen completed the reported follow-up. Eleven had paired bone biopsies, with ten evaluable for the primary histological endpoint. These denominators matter: a statement about fourteen participants does not mean that every reported biopsy comparison included fourteen paired observations. Missing samples and imputation affect the interpretation.

Osteoid volume relative to bone volume fell from a mean of 26.1% to 11.9%. The reported change was -54%, with a 95% confidence interval from -69% to -40% and P<.0001. This supports a substantial histological improvement in the examined adults. Osteoid surface was measured relative to bone surface, a different denominator from osteoid volume relative to bone volume.

The improvement was incomplete, and not every endpoint was statistically clear. Mineralisation lag time estimates the delay before newly formed bone material becomes mineralised. For the imputed analysis, the reported change was -83%, but the confidence interval extended from -95.1% to 51.8%, with P=.1094. This finding in the main Results qualifies the abstract’s broader statement that all measures improved significantly. The uncertainty should remain visible rather than being removed by the direction of the point estimate.

The uncontrolled design, small selected population, missing biopsies and disease-specific treatment restrict generalisation. Histology is a tissue endpoint; this report does not establish a reduction in fractures or an energy benefit from D3. Its value is a direct human connection between treatment of disordered phosphate regulation and improved, though incompletely normalised, bone mineralisation.

Phosphate deficiency separates resting ATP from recovery

Hettleman and colleagues compared phosphate-deficient and control mice after four weeks of different dietary phosphate exposure. They measured muscle force and nucleotide pools during stimulation and recovery. ATP, or adenosine triphosphate, is a molecule used in cellular energy transfer. Its amount at one moment is different from the rate at which it is regenerated.

Resting ATP did not clearly differ: 44±3 micromoles per gram of protein in control muscle versus 42±2 in deficient muscle, reported as mean±standard error, with P=.50. Recovery after the experimental contractions was impaired. At two minutes, force had recovered to about 46% in deficient animals versus 66% in controls. ATP recovery also differed, while some other measures, including normalised peak force and phosphocreatine recovery, did not show the same clear difference.

The authors interpreted the pattern as impaired ATP synthesis, but synthesis flux was not directly measured. The study measured pools and recovery, so that mechanistic inference should not be restated as a direct flux measurement. Deficient animals also weighed less, and the study did not use pair feeding to isolate every dietary consequence.

There was no vitamin D intervention or vitamin D status measurement in this experiment. Its role in this review is to explain a possible systemic consequence of phosphate disturbance. It does not show that taking vitamin D improves muscle energy, or that a normal resting ATP result excludes a recovery problem under other conditions.

Excess phosphate produces a different metabolic constraint

Peri-Okonny and colleagues examined the opposite exposure: excessive rather than deficient dietary phosphate. In their twelve-week mouse comparison, higher phosphate was associated with reduced measured fat oxidation and shorter exercise duration, without the same pattern of body-weight or cardiac-function change. The reported exercise times were approximately 651 versus 798 seconds.

The study’s indirect calorimetry and exercise results address fuel use and performance. They do not directly measure ATP produced per unit of oxygen, and should not be described as a universal measure of mitochondrial efficiency.

The publication also included an observational human analysis involving 1,603 participants. A serum-phosphate association with activity is not a randomized test of dietary phosphate, and cannot establish human dietary causality. The mouse experiment did not demonstrate that vitamin D mediated the effect. The principal report also has an unresolved sample-count presentation and a figure-caption panel-order mismatch. These inconsistencies limit precise interpretation of the reported group counts and panel assignments.

Together, the deficient: and excessive-phosphate experiments show why a single direction such as ‘more phosphate means more energy’ is inadequate. They used different models and outcomes, and neither tested vitamin D treatment. The scientifically justified link is that phosphate disturbance can constrain muscle metabolism under specified experimental conditions, within a regulatory system in which vitamin D participates.

What the combined evidence supports

The endocrine and consequence studies answer related questions. The first set explains how hormones and transport pathways participate in phosphate handling. The second examines the costs of disrupted handling for cartilage, bone and muscle. Connecting them does not demonstrate that manipulating vitamin D will reproduce every consequence observed after changing phosphate or FGF23 directly.

Evidence typeWhat the measurement establishesImportant boundary
Hormone and transporter experimentsSelected regulatory responses and transport routesModel, organ, form and timing matter
Human precursor trialsEffects of the tested D2 or D3 intervention on measured outcomesSeparate trials do not isolate a D2-versus-D3 difference
Growth-plate and bone modelsDevelopmental and mineralisation consequencesAnimal mineral rescue is not adult fracture prevention
Adult XLH bone biopsiesDisease-specific tissue response during FGF23-directed treatmentSmall uncontrolled study; not every endpoint was clear
Muscle deficiency and excess experimentsSelected energy-pool, fuel-use and recovery outcomesNo demonstrated human D3 energy benefit

Several findings prevent an overly simple account: active and passive intestinal routes behaved differently; a D3 trial had an overall FGF23 null result; uremic glands resisted an effect seen in normal glands; stable serum phosphate coexisted with altered flux; and removal of ectopic calcification accompanied worse skeletal disease. These qualifications are part of the physiological explanation.

Vitamin D Signalling Across Metabolism, Immunity and Endocrine Context: Evidence Review examines a related question about renal hormone timing and transcription across tissue contexts. The current evidence adds direct transport, disease-response, histological and metabolic distinctions. A transcript, a circulating concentration, a transport measurement and a functional outcome supply different information and should be interpreted together without making them interchangeable.

The twelve primary publications are complementary, not twelve independent confirmations of one effect. Stored human samples in later processing work came from the earlier D2 trial, and companion analyses of the Styrian trial do not constitute new randomized populations. Different experimental arms or multiple models in one paper likewise do not become separate clinical replications.

Conclusion

Vitamin D is part of conditional phosphate feedback involving intestine, kidney, bone and parathyroid glands. The assessed studies show selective transport and endocrine responses, important disease-context differences, and consequences of disturbed phosphate handling for mineralisation and muscle metabolism. They support a detailed physiological account while leaving human D3 effects on those downstream outcomes as a separate evidential question.

Primary sources and publication details

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. Shimada T and colleagues. Journal of Clinical Investigation. 2004;113:561 to 568. DOI: 10.1172/jci19081. PMID: 14966565.

Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Burnett-Bowie SA and colleagues. Clinical Journal of the American Society of Nephrology. 2012;7:624 to 631. DOI: 10.2215/cjn.10030911. PMID: 22300739.

The parathyroid is a target organ for FGF23 in rats. Ben-Dov IZ and colleagues. Journal of Clinical Investigation. 2007;117:4003 to 4008. DOI: 10.1172/jci32409. PMID: 17992255.

Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels. Gerber JS and colleagues. Pflügers Archiv. 2025;477:495 to 508. DOI: 10.1007/s00424-024-03046-4. PMID: 39601886.

Effects of vitamin D supplementation on FGF23: a randomized-controlled trial. Trummer C and colleagues. European Journal of Nutrition. 2019;58:697 to 703. DOI: 10.1007/s00394-018-1672-7. PMID: 29602956.

FGF23 fails to inhibit uremic parathyroid glands. Canalejo R and colleagues. Journal of the American Society of Nephrology. 2010;21:1125 to 1135. DOI: 10.1681/asn.2009040427. PMID: 20431039.

1,25(OH)2 vitamin D3 stimulates active phosphate transport but not paracellular phosphate absorption in mouse intestine. Hernando N and colleagues. Journal of Physiology. 2021;599:1131 to 1150. Accepted manuscript inspected. DOI: 10.1113/jp280345. PMID: 33200827.

Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Sabbagh Y, Carpenter TO and Demay MB. Proceedings of the National Academy of Sciences USA. 2005;102:9637 to 9642. DOI: 10.1073/pnas.0502249102. PMID: 15976027.

Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Sitara D and colleagues. American Journal of Pathology. 2006;169:2161 to 2170. DOI: 10.2353/ajpath.2006.060329. PMID: 17148678.

Defective adenosine triphosphate synthesis. An explanation for skeletal muscle dysfunction in phosphate-deficient mice. Hettleman BD and colleagues. Journal of Clinical Investigation. 1983;72:582 to 589. DOI: 10.1172/jci111006. PMID: 6874957.

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. Insogna KL and colleagues. Journal of Bone and Mineral Research. 2019;34:2183 to 2191. DOI: 10.1002/jbmr.3843. PMID: 31369697.

High-Phosphate Diet Induces Exercise Intolerance and Impairs Fatty Acid Metabolism in Mice. Peri-Okonny P and colleagues. Circulation. 2019;139:1422 to 1434. Early-online principal copy inspected. DOI: 10.1161/circulationaha.118.037550. PMID: 30612451.

Related reading

Original sources